Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 4;14(1):26.
doi: 10.1186/s13014-019-1225-0.

Driving developments in UK oesophageal radiotherapy through the SCOPE trials

S Gwynne  1   2 , E Higgins  3 , A Poon King  3 , G Radhakrishna  4 , L Wills  5 , S Mukherjee  6 , Maria Hawkins  6 , G Jones  5 , J Staffurth  5   7 , T Crosby  8
Affiliations

Driving developments in UK oesophageal radiotherapy through the SCOPE trials

S Gwynne et al. Radiat Oncol. .

Abstract

Background: The SCOPE trials (SCOPE 1, NeoSCOPE and SCOPE 2) have been the backbone of oesophageal RT trials in the UK. Many changes in oesophageal RT techniques have taken place in this time. The SCOPE trials have, in addition to adopting these new techniques, been influential in aiding centres with their implementation. We discuss the progress made through the SCOPE trials and include details of a questionnaire sent to participating centres. to establish the role that trial participation played in RT changes in their centre.

Methods: Questionnaires were sent to 47 centres, 27 were returned.

Results: 100% of centres stated their departmental protocol for TVD was based on the relevant SCOPE trial protocol. 4DCT use has increased from 42 to 71%. Type B planning algorithms, mandated in the NeoSCOPE trial, were used in 79.9% pre NeoSCOPE and now in 83.3%. 12.5% of centres were using a stomach filling protocol pre NeoSCOPE, now risen to 50%. CBCT was mandated for IGRT in the NeoSCOPE trial. 66.7% used this routinely pre NeoSCOPE/SCOPE 2 which has risen to 87.5% in the survey.

Conclusion: The results of the questionnaires show how participation in national oesophageal RT trials has led to the adoption of newer RT techniques in UK centres, leading to better patient care.

Keywords: Oesophagus; Quality assurance; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

NA

Consent for publication

NA

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rackley T, Leong T, Foo M, et al. Definitive Chemoradiotherapy for Oesophageal Cancer, a promising start on an exciting journey. Clin Oncol. 2014;26:533–540. - PubMed
    1. Gwynne S, Wijnhoven B, Hulshof M, et al. Role of Chemoradiotherapy in Oesophageal Cancer - adjuvant and neoadjuvant therapy. Clin Oncol. 2014;26:522–532. - PubMed
    1. Crosby T, Hurt C, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet. 2013;14:627–637. - PubMed
    1. Mukherjee S, Hurt C, Gwynne S, et al. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin. based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer. 2015;15:48. - PMC - PubMed
    1. SCOPE 2 Trials. 2017. https://clinicaltrials.gov/ct2/show/NCT02741856. Accessed Jan 2019.

MeSH terms